SHYNDEC(SH:600420) Zhi Tong Cai Jing·2026-01-12 10:15Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (国药威奇达), received approval from the National Medical Products Administration for a supplemental application regarding the injection of Piperacillin Sodium, which includes a new 1.0g specification and the approval of 0.5g, 1.0g, and 2.0g formulations to pass the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval allows for the introduction of a new 1.0g specification for Piperacillin Sodium injection [1]. - The formulations of 0.5g, 1.0g, and 2.0g have successfully passed the consistency evaluation for generic drug quality and efficacy [1]. - Piperacillin Sodium is primarily used for treating infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, including sepsis and various types of infections [1].